On January 31st, Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces a positive outcome following innovative pilot studies in multiple fibrotic diseases for its NXP002 programme.

This pilot study has been performed by FibroFind the University-based service facility embedded in Newcastle Fibrosis Research Group

Click HERE to download the report published by Nuformix